Across 7 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of The Cooper Companies news is Neutral (-2)
on a scale from −100 to +100.
That is down 5 points from the previous 30 days (+3).
📈 Cooper generated $678M free cash flow, up from $189M two years prior.
📉 Stock fell 13.3% despite 5.6% yield while underperforming the S&P 500.
Somewhat Bearish -25
Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
AI-generated analysis
Key insights
📈 Cooper Companies generated $678 million in free cash flow over the twelve months to July 31, 2026, representing a significant increase from $189 million two years prior.
📉 The stock price has declined 13.3% over the past year despite producing a 5.6% free cash flow yield, underperforming the S&P 500 which returned 12.2%.
📉 CooperVision's fiscal Q3 2026 revenue was flat year-over-year at $717 million, prompting management to cut its organic growth forecast for fiscal 2026 to 1.5%.
⚖️ Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation in the fertility business.
💸 Management expects approximately $272 million in litigation-related payments and $170 million in free cash flow for fiscal Q4, excluding these costs.
📉 Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value when netted against cash.
👷 Management plans to hire more salespeople in the U.S. to address a workforce that is smaller than its competitors'.
📈 Bullish signals
📈Cooper Companies produced free cash flow equal to 5.6% of its market value over the last twelve months, significantly higher than the 4.2% median for S&P 500 companies.
📈The company generated $678 million in free cash flow over the twelve months to July 31, 2026, up from $189 million two years earlier.
📈Fiscal Q3 delivered the highest quarterly free cash flow in Cooper's history, driven by stronger operations and lower capital spending.
📈Free cash flow has remained above zero in every twelve-month period since July 2023, demonstrating consistent operational cash generation.
💸Management aims for $2.2 billion of free cash flow across fiscal 2026 to 2028 despite plans to borrow more capital.
📉 Risk factors
📉Cooper's shares lost 13.3% over the past year while the S&P 500 returned 12.2%, indicating a significant market underperformance.
📉CooperVision's fiscal Q3 2026 revenue was essentially flat from a year earlier, with management cutting its organic growth forecast to 1.5% at the midpoint.
⚖️Operating margins fell to 12.8% from 18.3% a year earlier due to a $271.6 million charge taken in fiscal Q2 2026 to settle litigation.
💸Management expects roughly $272 million of free cash flow payments related to litigation in fiscal Q4, weighing on near-term cash.
📉Net debt stood at $2.39 billion as of July 31, 2026, representing 19.9% of the company's market value.
Article
Cooper Companies (COO) has generated significant free cash flow, producing 5.6% of its market value over the last twelve months compared to a 4.2% median for S&P 500 companies. Despite this strong cash generation, the stock price has underperformed the broader market, losing 13.3% over the past year while the S&P 500 gained 12.2%. Management attributes the low valuation to expectations of a shrinking business or high litigation costs, though recent data suggests the underlying cash flow remains robust.
The company operates through two main segments: CooperVision, which sells contact lenses, and CooperSurgical, which provides fertility and surgical products. Over the twelve months ending July 31, 2026, the business produced $678 million in free cash flow, a substantial increase from $189 million two years prior. This cash flow represented 16.0% of total revenue, with management noting that fiscal Q3 delivered the highest quarterly free cash flow in the company's history due to improved operations and lower capital spending.
However, growth concerns persist specifically within the contact lens division. CooperVision's revenue was essentially flat year-over-year in fiscal Q3 2026, leading management to cut its organic growth forecast for fiscal 2026 to 1.5% from a previous expectation of 4.0%. The slowdown is attributed to inventory adjustments and the phasing out of older hydrogel lenses. Additionally, operating margins declined to 12.8% from 18.3% a year earlier due to a significant $271.6 million charge taken in fiscal Q2 2026 to settle litigation in its fertility business.
Looking ahead, Cooper expects to face substantial cash outflows in fiscal Q4, including approximately $272 million in litigation-related payments and $170 million in free cash flow before those costs. The company has increased borrowing to fund these payments and share buybacks, with net debt standing at $2.39 billion as of July 31, 2026. Investors are advised to watch for the December 2026 earnings report, which will provide critical updates on CooperVision's organic growth trajectory and free cash flow performance after accounting for the anticipated litigation expenses.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
The Cooper Companies, Inc. (NASDAQ: COO) shares fell 6.57% on Friday, trading at $85 after hitting an all-time low of $82.61. The decline occurred despite the company reporting better-than-expected financial results for the first quarter of fiscal year 2025, where net income rose 28% to $104.3 million and net sales increased 3.5% to $964.7 million.
CEO Al White stated that the company met revenue expectations and exceeded operational targets at the start of the year. Looking ahead, The Cooper Companies expects total revenues to grow between 6% and 8% for the full year, with guidance ranging from $4.08 billion to $4.158 billion.
The stock's drop was driven by investor sentiment souring on missed earnings expectations relative to Wall Street consensus, even though the company's own performance metrics were positive. The article notes that COO ranked 7th among the worst-performing stocks in a broader list of ten companies that bucked wider market optimism following a strong finish for major indices.
📉 COO shares hit all-time low of $82.61 after dropping 6.57%.
💰 Q1 net income surged 28% to $104.3 million.
📈 Net sales grew 3.5% to $964.7 million, beating expectations.
🔮 Full-year revenue guidance set between 6% and 8% growth.
🗣️ CEO Al White confirmed operational targets were met.
📉 COO shares dropped 6.57% to close at $85, hitting an all-time low of $82.61 on Friday.
💰 Q1 FY2025 net income surged 28% year-over-year to $104.3 million despite the stock decline.
📈 Net sales grew 3.5% to $964.7 million, exceeding revenue expectations for the quarter.
🔮 Full-year revenue guidance is set between 6% and 8% growth, totaling $4.08B to $4.158B.
🗣️ CEO Al White confirmed the company met operational targets and remains confident in future growth.
📊 The stock ranked 7th on a list of ten worst-performing names despite a strong market finish.
Bullish Signals
Net income rose 28% to $104.3 million in Q1 FY2025.
Net sales increased 3.5% year-over-year to $964.7 million.
Full-year revenue guidance targets 6-8% growth.
Company exceeded operational targets at the start of the year.
Risk Factors
Shares fell 6.57% to all-time low of $82.61.
Missed earnings expectations relative to Wall Street consensus.
Bullish Signals
Net income rose 28% to $104.3 million in Q1 FY2025, demonstrating strong profitability.
Net sales increased 3.5% year-over-year to $964.7 million, showing solid top-line growth.
The company provided full-year revenue guidance of 6-8% growth, indicating management confidence.
CEO Al White confirmed that the company exceeded operational targets at the start of the year.
Risk Factors
Shares fell 6.57% to an all-time low of $82.61 due to investor disappointment over missed earnings expectations relative to Wall Street consensus.
The stock underperformed significantly despite positive internal financial results, suggesting a disconnect between company performance and market sentiment.
Boston Trust Walden Corp reduced its stake in The Cooper Companies, Inc. (NASDAQ: COO) by 6.3% during the first quarter, selling 77,917 shares to hold a remaining position of 1,159,562 shares valued at approximately $82.9 million. While this major institutional holder decreased its exposure, several smaller hedge funds and investment advisors significantly increased their positions in the fourth or third quarters, with holdings ranging from roughly 300 to 485 shares each.
Wall Street analysts have issued mixed signals regarding COO stock following recent performance data. Piper Sandler maintains an 'overweight' rating with a $86 price objective, while Wall Street Zen upgraded the stock to a 'buy.' Conversely, Wells Fargo downgraded the rating to 'sell' with a $66 target, and JPMorgan Chase lowered its price objective to $71, reflecting divergent views on the company's near-term trajectory.
The Cooper Companies operates as a global medical device firm headquartered in San Ramon, California, focusing primarily on vision care through CooperVision and women's health via CooperSurgical. Financial metrics show a market capitalization of $14.47 billion with a P/E ratio of 62.88, while the stock trades between its 52-week low of $58.89 and high of $89.83, currently hovering near its 200-day moving average.
📉 COO stake dropped 6.3% to $82.9M in Q1.
📈 Small funds like Root Financial rose over 100%.
🏦 Institutional ownership stands at 24.39% of shares.
💰 Market cap is $14.47B with a P/E of 62.88.
📊 Analyst consensus is 'Hold' with a $81.31 target.
📉 Boston Trust Walden Corp reduced its COO stake by 6.3% in Q1, selling 77,917 shares while retaining a $82.9 million position.
📈 Smaller funds like Root Financial Partners and True Wealth Design significantly increased their holdings by over 100% and 480% respectively in recent quarters.
🏦 Institutional ownership of The Cooper Companies stands at 24.39% as of the latest SEC filings.
💰 COO trades with a market cap of $14.47 billion and a P/E ratio of 62.88, reflecting high valuation expectations for its medical device segments.
📊 Analyst consensus is mixed with an average 'Hold' rating and a target price of $81.31, though Wells Fargo has issued a 'sell' rating at $66.
🔍 Piper Sandler maintains an 'overweight' stance with a $86 price objective, contrasting with JPMorgan's lowered target of $71.
👁️ The company operates two main segments: CooperVision for soft contact lenses and CooperSurgical for women's health products.
📈 Stock technicals show COO trading above its 50-day moving average of $64.36 but below its 200-day average of $73.37.
Bullish Signals
Piper Sandler maintains an overweight rating with $86.00 price target.
Wall Street Zen upgraded rating from hold to buy.
Hedge funds increased stakes despite major institutional reduction.
Risk Factors
Wells Fargo lowered target to $66.00 with sell rating.
JPMorgan reduced objective to $71.00 and assigned neutral.
Robert W. Baird cut target from $98.00 to $85.00.
Bullish Signals
Piper Sandler maintains an 'overweight' rating with a specific price objective of $86.00, indicating confidence in the company's growth potential.
Wall Street Zen upgraded its rating from 'hold' to 'buy', signaling a positive shift in analyst sentiment regarding the stock.
Multiple smaller hedge funds have aggressively increased their stakes, suggesting interest from capital allocators despite the major institutional reduction.
Risk Factors
Wells Fargo & Company reissued a 'sell' rating and lowered its price target to $66.00, down from $82.00, highlighting bearish concerns.
JPMorgan Chase reduced its price objective from $80.00 to $71.00 and assigned a 'neutral' rating, reflecting caution on the stock's valuation.
Robert W. Baird cut its target price from $98.00 to $85.00, indicating a downward revision in expected performance.
The London Company's fourth-quarter 2025 investor letter highlights The Cooper Companies, Inc. (NASDAQ: COO) as a featured holding within its Mid Cap Strategy portfolio. While the broader market saw gains in Q4 2025, the strategy outperformed the Russell Midcap Index, driven by specific stock selection and sector exposure that included positions in medical device firms like Cooper.
Cooper operates through two main segments: CooperVision, which generates over 65% of revenue from contact lenses in an oligopolistic market with four dominant players, and CooperSurgical, focused on women's healthcare products. The company benefits from high customer switching costs and a diverse product portfolio, though current margins are trailing peers due to ongoing capital investments and industry headwinds.
Investment analysts note that recent share price weakness is attributed to cyclical pressures and execution issues rather than fundamental deterioration. Key bullish factors include significant potential for margin expansion as capital spending moderates, attractive valuation levels, and insider buying signaling confidence. Additionally, activist involvement is cited as a potential catalyst for operational improvements and possible business separation.
Despite these strengths, the article notes that Cooper is not currently among the top 30 most popular stocks held by hedge funds, with holdings dropping slightly from 56 to 53 portfolios in Q4 2025. The London Company suggests that while Cooper offers promise, other AI-focused stocks may offer higher returns and shorter time frames for investors seeking aggressive growth.
📈 Top holding in London Company Mid Cap Strategy Q4 2025.
💰 CooperVision dominates 65% revenue in oligopolistic contact lens market.
📉 Shares closed $83.56 on Feb 24, 2026, with $16.6B cap.
🛠️ Margins trail peers due to multi-year investment cycle headwinds.
🚀 Margin expansion expected as capital spending moderates soon.
📈 The London Company Mid Cap Strategy featured The Cooper Companies (COO) as a top holding in its Q4 2025 investor letter.
💰 CooperVision accounts for over 65% of revenue, operating in an oligopolistic contact lens market where four players control 95% share.
📉 Shares lost 8.17% over the last 52 weeks but closed at $83.56 per share on February 24, 2026, with a market cap of $16.6 billion.
🛠️ Margins currently trail peers due to a multi-year investment cycle and industry headwinds affecting the medical device sector.
🚀 Significant margin expansion potential exists as capital spending moderates and capacity utilization improves in the coming quarters.
👔 Activist involvement is identified as a key catalyst for operational improvements and potential business separation of divisions.
💼 Recent insider buying signals confidence in the company's long-term fundamentals despite recent cyclical price weakness.
📊 53 hedge fund portfolios held COO at the end of Q4 2025, down from 56 in the previous quarter.
🧠 The London Company suggests AI stocks may offer higher returns and shorter time frames compared to Cooper's current profile.
🏥 Cooper operates two distinct segments: CooperVision (contact lenses) and CooperSurgical (women's healthcare products).
Bullish Signals
Four players control 95% of the industry market.
Diverse portfolio drives above-market growth rates.
High switching costs create a durable moat.
Valuation is attractive relative to peers.
Insider buying signals management confidence.
Activist involvement could lead to separation.
Margin expansion potential as spending moderates.
Risk Factors
Margins trail peers due to multi-year investment cycle and headwinds.
Stock lost 8.17% value over last 52 weeks.
Not in top 30 hedge fund popular stocks list.
Hedge fund holdings dropped from 56 to 53 portfolios.
Bullish Signals
CooperVision dominates a high-quality, oligopolistic market with four players controlling 95% of the industry, providing strong pricing power.
The company possesses a diverse product portfolio and deep customer relationships that drive above-market growth rates.
High customer switching costs create a durable competitive moat within the contact lens and women's healthcare segments.
Valuation is currently attractive relative to peers, presenting a potential entry point for long-term investors.
Recent insider buying activity signals management confidence in the company's future prospects despite recent stock weakness.
Activist involvement serves as a catalyst for operational improvements and could lead to strategic business separation.
Significant margin expansion potential is available as capital spending moderates and capacity utilization improves.
Risk Factors
Current operating margins trail peers due to a multi-year investment cycle and ongoing industry headwinds.
The stock has lost 8.17% of its value over the last 52 weeks, reflecting recent cyclical pressures and execution missteps.
Cooper is not included in the list of 30 most popular stocks among hedge funds, indicating lower institutional consensus compared to peers.
Hedge fund holdings decreased from 56 portfolios in the previous quarter to 53 at the end of Q4 2025.
Stifel Securities has reiterated a Buy rating on Cooper Companies (NASDAQ: COO) with a price target of $85, following the company's announcement that it is advancing discussions to sell its surgical business unit, CooperSurgical. The brokerage views the recent settlement of all legal issues plaguing the unit as a positive signal that management is moving the sale talks to the next level, with multiple interested parties identified.
Upon completion of the divestiture, Stifel estimates Cooper's stock could be worth $80 per share, representing approximately 21% upside from current levels. The company plans to utilize the vast majority of proceeds from the sale to fund share repurchases. This strategic move would transform Cooper into a focused contact lens manufacturer under its CooperVision unit.
Cooper Companies operates two primary divisions: CooperVision, which produces contact lenses for vision correction, and CooperSurgical, focused on women's health products including genetic testing and fertility solutions. While the article notes that some analysts believe AI stocks offer higher returns, it highlights specific bullish metrics for COO, including backing from 49 hedge funds and a recommendation from billionaire Barry Rosenstein.
📈 Stifel rates Cooper Companies Buy with $85 price target.
💰 Proceeds from surgical sale will fund share repurchases.
⚖️ All legal issues regarding the surgical unit are settled.
👁️ Company will focus exclusively on contact lens business.
🤝 Multiple parties expressed interest in buying the surgical unit.
📈 Stifel reiterated a Buy rating on Cooper Companies (COO) with a price target of $85 following progress in selling the surgical unit.
💰 The company plans to use the majority of proceeds from the CooperSurgical sale to fund share repurchases.
⚖️ All legal issues plaguing the CooperSurgical business unit have been settled, clearing the path for a potential divestiture.
👁️ Post-sale transformation will leave Cooper focused exclusively on its contact lens business under the CooperVision unit.
📊 Analysts estimate the stock could reach $80 per share after the sale, indicating roughly 21% upside from current prices.
🤝 Multiple parties have expressed interest in buying the surgical business unit according to company disclosures.
🏛️ Cooper Companies operates two main divisions: CooperVision for contact lenses and CooperSurgical for women's health products.
Bullish Signals
Stifel Buy rating with $85 price target.
Legal issues resolved, facilitating planned sale.
Majority of proceeds used for share repurchases.
Multiple parties interested in purchasing business.
Billionaire Barry Rosenstein identifies COO as best buy.
Bullish Signals
Stifel maintains a Buy rating with a specific price target of $85, suggesting strong analyst confidence in the company's valuation.
The settlement of all legal issues regarding the surgical unit removes a significant overhang and facilitates the planned sale.
Management intends to use the majority of the sale proceeds for share repurchases, which typically supports or boosts the stock price.
Multiple parties are actively interested in purchasing the CooperSurgical business, indicating strong market demand for the asset.
Billionaire Barry Rosenstein identifies COO as one of the best stocks to buy, adding high-profile institutional endorsement.
The company is backed by 49 hedge funds, demonstrating broad institutional ownership and confidence in the investment thesis.
Cooper Companies (COO) shares rose 7.3% following its Q2 2026 earnings beat, where both revenue and adjusted EPS surpassed Wall Street estimates. Despite this short-term momentum, the stock remains down 18.7% year-to-date and 5.6% over the last year. The article highlights a narrative suggesting the company is undervalued at its current price of $65.91 compared to an implied fair value of approximately $87.
The bullish case rests on expectations that free cash flow will increase as capital expenditure cycles wind down following the ramp-up of MyDAY capacity. Management guides for roughly $2 billion in free cash flow over the next three years, driven by strong cost discipline and revenue momentum. This improved cash generation is expected to benefit shareholders through debt reduction and share repurchases.
However, significant valuation concerns persist as the stock trades at a P/E ratio of 54.5x, which is substantially higher than its own fair estimate of 32.5x, the peer average of 23.1x, and the industry average of 24.4x. The article notes that investors are paying a premium, raising questions about whether future earnings can support this multiple.
Key risks include slower growth in the contact lens market, pricing competition, uncertainty surrounding the transition from Clariti to MyDAY, and softer demand for fertility products and IUDs. While the cash flow outlook is positive, the high valuation multiple suggests the market may already be pricing in future growth or anticipating challenges in these specific segments.
📈 Stock jumped 7.3% after Q2 2026 earnings beat.
💰 Management guides $2B free cash flow for next three years.
⚖️ P/E of 54.5x is significantly higher than fair estimate of 32.5x.
📉 Stock down 18.7% year-to-date despite recent positive earnings momentum.
Cooper Companies (NASDAQ:COO) reported record revenue of $1.08 billion and non-GAAP earnings per share of $1.21 for the fiscal second quarter of 2026, representing an 8% year-over-year increase in revenue and a 26% rise in earnings. The company achieved its 10th consecutive quarter of beating consensus estimates, with organic consolidated revenue growth of 5%. CEO Albert White attributed results to steady execution, innovation, and market share gains, while CFO Brian Andrews noted that operating income rose 19% to an operating margin of 27.5%.
The company's two main segments showed mixed but generally positive performance. CooperVision revenue increased 8% to $724 million, driven by strong growth in premium lenses in the Americas and demand for MyDay and MiSight products in Europe. However, Asia-Pacific revenue declined 6% due to portfolio repositioning and consumer weakness in Japan and China. CooperSurgical revenue rose 8% to $358 million, with fertility sales up 10% and surgical products growing 4%, though PARAGARD revenue remained flat.
A significant development involves the resolution of litigation related to a December 2023 embryo culture media recall. The company reached settlements covering over 95% of claimants, recording a net charge of $271.6 million which was excluded from non-GAAP earnings. This resolution allows management to advance strategic discussions regarding CooperSurgical, with the CEO noting robust interest from multiple parties and the potential for an update before the next earnings call if progress is made.
Cooper updated its fiscal 2026 guidance, raising the revenue outlook to $4.28-$4.32 billion and non-GAAP EPS guidance to $4.58-$4.66. Free cash flow guidance was raised to approximately $650 million for the year, excluding litigation payouts, with a long-term view of generating $2.2 billion in free cash flow from 2026 through 2028. Management expects gross margins to decline slightly in the third quarter due to unfavorable foreign exchange and higher costs including tariffs, but plans to be more aggressive on share repurchases following the current quarter's conservative stance.
📈 Record Q2 revenue of $1.08B and EPS of $1.21.
👁️ CooperVision grew 8% driven by premium lens strength.
🔬 CooperSurgical fertility revenue rose 10% to $144M.
⚖️ Settled 95% of recall claims with $271.6M charge.
💰 Raised 2026 FCF guidance to ~$650M excluding payouts.
📈 Cooper Companies reported record Q2 revenue of $1.08 billion (+8% YoY) and non-GAAP EPS of $1.21 (+26%), marking the 10th consecutive quarter of beating consensus.
👁️ CooperVision segment grew 8% to $724 million, led by premium lens strength in the Americas and double-digit growth for the MyDay brand.
📉 Asia-Pacific revenue declined 6% due to consumer weakness in Japan and China, alongside a strategic shift away from legacy hydrogel products.
🔬 CooperSurgical fertility revenue increased 10% organically to $144 million, driven by U.S. strength and restocking activity in the Middle East.
⚖️ The company settled over 95% of claims related to a December 2023 embryo culture media recall, recording a net charge of $271.6 million.
🤝 Management confirmed robust interest from multiple parties in CooperSurgical and stated that litigation resolution removes barriers to advancing strategic discussions.
💰 Free cash flow guidance for fiscal 2026 was raised to roughly $650 million, excluding litigation payouts, with a long-term target of $2.2 billion through 2028.
📊 Fiscal 2026 revenue guidance was updated to $4.28-$4.32 billion, reflecting 5-6% reported growth and 3.5-4.5% organic growth.
🔄 Gross margin guidance for Q3 is lowered to around 66% due to unfavorable FX, tariffs, freight costs, and inventory reduction from a new AI system.
📉 Cooper plans to be more aggressive on share repurchases in the future after using cash to reduce net debt to $2.3 billion this quarter.
Bullish Signals
Record revenue $1.08B and EPS $1.21 up 26% YoY.
Beat earnings consensus for 10 consecutive quarters.
Americas premium lenses grew 7% on high-margin strength.
Fertility revenue rose 10% organically with strong equipment sales.
Litigation resolved enabling strategic reviews and buyback capacity.
Risk Factors
Asia-Pacific revenue declined 6% due to consumer weakness.
$271.6 million charge for embryo culture media recall settlements.
Gross margins expected to decline to around 66% in Q3.
CooperVision faces challenges in Asia-Pacific e-commerce channels.
PARAGARD revenue was flat despite being ahead of expectations.
Bullish Signals
Record revenue of $1.08 billion and non-GAAP EPS of $1.21 represent a 26% increase year-over-year.
The company has achieved 10 consecutive quarters of exceeding consensus earnings expectations.
CooperVision premium lenses in the Americas grew 7%, supported by strength in high-margin products.
CooperSurgical fertility revenue increased 10% organically, with strong performance in capital equipment and genomics.
The resolution of the embryo culture media litigation allows management to proceed with strategic reviews without legal hindrances.
Robust interest has been received from multiple parties regarding CooperSurgical, indicating high valuation potential.
Free cash flow guidance was raised to $650 million for fiscal 2026, excluding one-time litigation costs.
The company maintains a strong balance sheet with net debt reduced to $2.3 billion and a history of buybacks.
Risk Factors
Asia-Pacific revenue declined 6% due to consumer weakness in key markets like Japan and China.
A net charge of $271.6 million was recorded for the embryo culture media recall settlements, impacting GAAP earnings.
Gross margins are expected to decline year-over-year, with Q3 projected at around 66% due to tariffs and FX headwinds.
CooperVision faces challenges in Asia-Pacific where it is less strong in e-commerce channels compared to practitioner channels.
PARAGARD revenue was flat, which management noted was ahead of expectations but still represents stagnation.
The Cooper Companies reported a fiscal second-quarter loss of $77.9 million, or 40 cents per share, though adjusted earnings came to $1.21 per share after accounting for one-time gains and costs. These results exceeded Wall Street expectations, with the average analyst estimate from Zacks Investment Research projecting earnings of $1.10 per share. Revenue for the period reached $1.08 billion, surpassing the consensus forecast of $1.05 billion among six surveyed analysts.
Looking ahead, The Cooper Companies expects full-year earnings to fall between $4.58 and $4.66 per share, with revenue anticipated in the range of $4.29 billion to $4.32 billion. The company manufactures surgical and contact lens products and is based in San Ramon, California. This story was generated by Automated Insights using data from Zacks Investment Research.
📉 Cooper Companies posted a Q2 loss of $77.9 million per share.
💰 Adjusted earnings of $1.21 beat analyst estimates at $1.10.
📈 Revenue hit $1.08 billion, surpassing the $1.05 billion forecast.
🔭 Full-year earnings projected between $4.58 and $4.66 per share.
💵 Expected annual revenue ranges from $4.29 to $4.32 billion.
📉 The Cooper Companies reported a fiscal Q2 loss of $77.9 million, translating to a 40-cent per-share loss.
💰 Adjusted earnings for one-time items came in at $1.21 per share, surpassing analyst estimates of $1.10.
📈 Revenue reached $1.08 billion during the quarter, exceeding the Street forecast of $1.05 billion.
🔭 The company projects full-year earnings between $4.58 and $4.66 per share.
💵 Full-year revenue is expected to fall within the range of $4.29 billion to $4.32 billion.
🏢 The San Ramon, California-based manufacturer produces surgical and contact lens products.
📊 Results were based on data from Zacks Investment Research and beat expectations from six surveyed analysts.
Bullish Signals
Cooper Companies adjusted earnings hit $1.21/share vs $1.10 estimate.
Q2 revenue reached $1.08B, beating the $1.05B forecast.
Full-year earnings guidance stands at $4.58-$4.66 per share.
Revenue guidance set at $4.29-$4.32 billion for sustained demand.
Risk Factors
Company lost $77.9M in Q2, or 40 cents per share.
Bullish Signals
The Cooper Companies reported adjusted earnings of $1.21 per share, surpassing the average analyst estimate of $1.10 per share.
Revenue reached $1.08 billion in fiscal Q2, exceeding Wall Street forecasts which anticipated $1.05 billion.
The company's full-year guidance remains strong with expected earnings between $4.58 and $4.66 per share.
Full-year revenue guidance is set at a range of $4.29 billion to $4.32 billion, indicating sustained demand for surgical and contact lens products.
Risk Factors
The company reported a fiscal second-quarter loss of $77.9 million, or 40 cents per share.
CooperCompanies (COO) recently delivered its Q2 earnings results and provided an updated guidance outlook, drawing significant attention from investors regarding its revenue trends and margin performance. The medical device manufacturer operates through two primary business segments: CooperVision, which produces contact lenses, and CooperSurgical, which supplies products for women's health and fertility care. This dual-business model offers a mix of recurring demand from the consumer-driven contact lens replacement cycle and more volatile, procedure-based revenue from the surgical segment that is sensitive to healthcare spending trends and hospital purchasing volumes.
For investors in the U.S., the company represents a defensive yet growth-oriented play within the healthcare sector, combining exposure to long-duration demographic trends with international revenue streams. The analysis highlights that CooperVision remains the most visible driver due to its broad consumer and professional user base, where subscription-like replacement habits and prescription shifts heavily influence sentiment. Conversely, CooperSurgical relies on clinical procedure volumes, making it susceptible to adjustments in hospital buying patterns or demographic shifts in fertility care demand.
Market focus during the earnings call centered on whether management could demonstrate stable growth across both business lines while successfully protecting gross margins amidst potential pressure. The guidance update and commentary on regional demand, particularly in the United States and other developed markets, are seen as critical catalysts for stock sentiment rather than just the headline revenue figures. Additionally, the article notes that currency fluctuations and foreign demand can impact reported results, adding another layer of complexity to the company's valuation which heavily depends on consistent execution and credible forward-looking statements. The consensus among investors is that even modest disappointments in outlook or margin quality could negatively affect the stock, given its defensive classification paired with high expectations for steady performance.
👁️ Recurring contact lens demand pairs with distinct women's health revenue streams.
💹 Investors watch margins, currency exposure, and demographic tailwinds for growth signals.
⚠️ Sharp stock reactions often follow guidance misses or deceleration in volume.
👁️ CooperVision's contact lens business provides recurring demand driven by prescription trends and international market expansion.
🏥 CooperSurgical offers a distinct revenue stream linked to women's health, fertility care, and hospital purchasing cycles.
📈 Investors closely monitor quarterly reports for signals of broad-based growth rather than reliance on a single product line.
💹 Gross margins are under scrutiny as management discusses pricing discipline and potential pressure from healthcare spending trends.
🌎 The company combines U.S. market relevance with significant international revenue exposure, making it sensitive to currency fluctuations.
⚖️ The two-segment structure offers diversification benefits but can make overall performance interpretation more complex for analysts.
🛡️ CooperCompanies is often viewed as a defensive healthcare stock capable of steady growth if execution remains consistent.
⚠️ Even modest disappointments in guidance or margin trends can lead to sharp negative reactions in the stock price.
📅 The latest Q2 results and outlook discussion have placed the company on investor watchlists following its earnings release.
💡 Management's ability to sustain demand across both business lines is considered the primary catalyst for future stock performance.
👥 Commentary from management regarding product launches and regional demand shifts often drives trading activity more than top-line revenue alone.
📉 Any deceleration in contact lens volume growth or surgical procedure volumes could impact overall stock sentiment significantly.
🌍 Foreign demand fluctuations remain a key variable affecting the company's reported financial results for U.S. investors.
🔬 Long-term demographic trends continue to support the women's health and fertility care portfolio within CooperSurgical.
💰 Investors prioritize consistent execution and credible guidance over isolated headline revenue numbers.
⏳ Future quarterly reports will likely determine whether current cautious sentiment improves or persists in the coming quarters.
🚀 The company is valued based on its link to long-duration health trends rather than cyclical industrial patterns.
📊 Healthcare investor sentiment heavily influences how the market values this specific company given its global exposure.
🛒 Repeat purchasing models for contact lenses contrast with the sensitivity of surgical products to clinical buying patterns.
🧬 The medical-device sector context means valuation depends heavily on the quality of operational execution by leadership.
📰 Additional stock developments can be tracked via investor relations pages and specialized equity coverage platforms.
Bullish Signals
CooperVision drives recurring demand for CooperCompanies.
Company benefits from growing women's health trends.
Stock offers defensive stability with steady expansion potential.
Diversified business reduces reliance on single product lines.
Global operations diversify revenue beyond the U.S. market.
Risk Factors
Margin pressure raised post-quarterly update.
Portfolio revenue declines from health spending drops.
Currency moves hurt results despite US focus.
Shares drop if growth and demand soften.
Modest disappointments punished with weak outlook.
Bullish Signals
CooperCompanies maintains a diversified business model with two distinct engines: CooperVision contact lenses, which drive recurring demand, and CooperSurgical products tied to women's health and fertility care.
The company benefits from exposure to long-term demographic trends in the healthcare sector, particularly within the sensitive but growing women's health market.
CooperCompanies operates as a defensive yet growth-capable stock, offering stability for investors while maintaining the potential for steady expansion driven by recurring product sales.
Management has signaled that the business is not overly reliant on single product lines, reducing risk associated with one-off purchasing cycles.
The global nature of the business allows exposure to international demand, diversifying revenue streams beyond just the U.S. market.
Risk Factors
Margin pressure is highlighted as a key concern following the latest quarterly update.
The surgical and fertility portfolio is sensitive to healthcare spending trends and procedure volumes, which can lead to revenue declines.
Currency moves and foreign demand fluctuations can negatively affect reported results despite U.S. relevance.
If both contact lens growth and surgical demand soften simultaneously, shares can react quickly to signs of fading momentum.
The market may punish even modest disappointments if the future outlook weakens for this defensive healthcare stock.
Investors are watching closely for any guidance shifts that could signal concerns about healthcare spending or consumer behavior trends.
Cooper-Standard reported first-quarter 2026 sales of $686.4 million, representing a 2.9% increase from the same period in 2025, driven by favorable foreign exchange rates despite lower volume and mix adjustments. Gross margin expanded to 12.0%, up 40 basis points year-over-year, with management attributing this improvement to effective cost controls amid production challenges in North America. However, Adjusted EBITDA decreased to $51 million from $58.7 million a year prior, primarily due to the absence of approximately $10 million in royalty payments received in the first quarter of 2025; excluding this one-time variance, margins would have shown improvement. On a GAAP basis, the company posted a net loss of $33.3 million compared to a net income of $1.6 million in the previous year, with an adjusted net loss of $5.2 million versus $3.5 million of income year-ago.
Chief Executive Officer Jeff Edwards and Chief Financial Officer John Banas highlighted operational resilience, noting a 99% green customer scorecard for quality and service during the quarter. Safety performance remained strong with a total incident rate of 0.18 per 200,000 hours worked, well below the company's benchmark. Management implemented cost-saving initiatives that generated $17 million in savings from lean operations, additional restructuring benefits of $2 million, and lower administrative costs of $1 million. These gains were partially offset by unfavorable volume and mix pressures of $7 million, higher inflation-related wage costs of $7 million, and $2 million in foreign exchange impacts.
The company maintained total liquidity of approximately $286 million as of March 31, 2026, comprising $118 million in cash and $167 million in availability on an unused asset-based lending facility. A refinancing transaction completed earlier in the quarter lowered overall interest costs and extended note maturities to 2031, with expectations to reduce annual cash interest by about $6 million. Cooper-Standard secured $128 million in net new business awards during Q1, surpassing its plan and positioning it to exceed its full-year target of more than $400 million. The product mix included roughly 60% Fluid Handling and 40% Sealing, with a strategic focus on fluid products for hybrid vehicle programs which offer significantly higher content per vehicle than traditional internal combustion engine solutions.
📈 Q1 sales rose 2.9% to $686M, though adjusted EBITDA fell 13% due to missing royalties.
💰 Gross margin improved 40 bps to 12.0%, offset by inflation and launch investments.
🏭 Liquidity remains strong with refinancing extending debt maturity to 2031 at lower rates.
🛡️ Safety and quality targets were met, driving net new business awards of $128M.
📈 First-quarter 2026 sales rose 2.9% to $686.4 million, driven by favorable foreign exchange despite volume mix challenges.
💰 Gross margin improved 40 basis points year-over-year to 12.0% of sales, described as a strong result given production headwinds.
⚖️ Adjusted EBITDA fell 13% to $51 million primarily due to non-recurrence of $10 million in royalty payments from the prior year.
💸 GAAP reported net loss widened to $33.3 million compared with a net income of $1.6 million in the first quarter of 2025.
🏭 Capital expenditures increased to $24 million (3.5% of sales) due to higher launch-related investments.
💸 Total costs were offset by $17 million in savings from lean initiatives and prior restructuring actions.
📉 Inflationary pressures including higher wages and input costs added $9 million to costs, with headwinds expected to increase in Q2.
🛡️ Management noted the company is "fairly well protected" against rising input costs like oil and aluminum through contractual indexes covering over 70% of exposure.
💰 The company maintained strong liquidity with $118 million in cash and $286 million total including unused facility availability.
🏦 Refinancing completed in April lowered the overall interest rate, reducing annual cash interest by about $6 million and extending note maturity to 2031.
📋 CEO Jeff Edwards highlighted operational excellence with 99% green customer scorecards for quality and service in Q1 2026.
⚠️ Safety performance remained strong with an incident rate of 0.18 per 200,000 hours worked, below the world-class benchmark of 0.35.
📊 Net new business awards totaled $128 million in Q1, ahead of plan and supporting a full-year goal of over $400 million.
🌐 Approximately 60% of first-quarter business awards were in Fluid Handling, with the majority based in North America.
🔋 CEO Jeff Edwards predicted continued growth for Fluid Handling due to increasing content per vehicle in hybrid programs.
🎯 Management reiterated a long-term target to double the Fluid Handling business within the next five to seven years.
Bullish Signals
Sales reached $686.4M, up 2.9% year-over-year.
Gross margin expanded 40 bps to 12.0%.
Operational excellence achieved with 99% quality scorecards.
Safety incident rate of 0.18 beats industry benchmark.
$17M in savings offset inflationary pressures.
Net new awards hit $128M, nearing $400M goal.
Hybrid programs double content per vehicle.
Target: Double Fluid Handling business in 5-7 years.
Total liquidity stood at $286M as of March 31.
Refinancing extended note maturity to 2031.
Risk Factors
GAAP net loss rose to $33.3M vs prior year income.
Adjusted EBITDA fell $7.7M due to missing Q1 royalties.
Inflation headwinds expected to intensify significantly in Q2.
Liquidity of $286M faces seasonal working capital outflows.
50%+ new business concentrated in high-risk China market.
Bullish Signals
Cooper-Standard reported higher first-quarter sales, reaching $686.4 million, which represents a 2.9% year-over-year increase driven by favorable foreign exchange.
Gross margin improved significantly to 12.0% of sales, a 40 basis point expansion from the prior-year period despite production volume headwinds on key North American platforms.
Management highlighted strong operational excellence with 99% green customer scorecards for quality and service, as well as 97% green scorecards for new program launches in 2026.
Safety performance remains world-class with a total incident rate of 0.18 per 200,000 hours worked, comfortably below the industry benchmark of 0.35.
The company delivered $17 million in savings from lean initiatives and cost-saving programs during the quarter, offsetting various inflationary pressures.
Cooper-Standard received $128 million in net new business awards in Q1, positioning it to pursue its full-year goal of more than $400 million in net new awards.
The Fluid Handling segment is expected to benefit significantly from growth in hybrid vehicle programs, which produce more than double the content per vehicle compared with traditional internal combustion engine programs.
Company leadership reiterated a long-term target to double its Fluid Handling business within the next five to seven years, expressing confidence in achieving this goal through recent wins and opportunities.
Cooper-Standard strengthened its balance sheet with total liquidity of about $286 million as of March 31, 2026, including $167 million of availability on its unused asset-based lending facility.
Refinancing completed on March 4 lowered the overall interest rate and extended the maturity on newly issued notes to 2031, providing enhanced financial flexibility.
Risk Factors
Adjusted EBITDA declined year-over-year by $7.7 million due primarily to the non-recurrence of approximately $10 million in royalty payments received in Q1 2025.
On a GAAP basis, the company reported a net loss of $33.3 million compared to net income of $1.6 million in the same period last year.
Adjusted net loss was $5.2 million per quarter versus adjusted net income of $3.5 million in Q1 2025.
Management warns that inflationary pressure headwinds were not significant in Q1 but are expected to intensify in Q2 due to the timing of oil price ramp-up.
There is a recognized lag between cost increases and the ability to pass those costs through to customers via price recoveries.
Total liquidity stands at approximately $286 million, which includes $167 million from an unused asset-based lending facility.
The company expects to unwind about $118 million in cash over the next couple of quarters due to typical seasonal working capital changes.
Cost savings initiatives are being offset by multiple headwinds including $7 million of unfavorable volume and mix, $7 million of higher wages and general inflation, and $2 million of unfavorable foreign exchange.
Over 50% of first-quarter new business awards are based in China, introducing geographic concentration risk.
Rocket Companies, operating under its Rocket Mortgage brand, filed a lawsuit against rival lender United Wholesale Mortgage (UWM) in the Supreme Court of the State of New York, alleging a willful and wanton breach of non-solicitation obligations owed to Mr. Cooper Group, which Rocket acquired earlier in 2024. The dispute centers on financial incentives offered by UWM to encourage brokers to refinance mortgages that had already been sold with servicing rights to Mr. Cooper in the first half of 2024, a transaction valued at approximately $773 million for nearly 182,000 loans.
Rocket's complaint details specific mechanisms used allegedly to violate these terms, including a program called Refi Shield 100 led by UWM chairman and CEO Mat Ishbia, which offered brokers a 1% reduction in refinance interest rates exclusively for borrowers serviced by Mr. Cooper. The lawsuit also identifies two additional initiatives launched in the fall of 2024: a 75-basis-point rate reduction program and a proprietary technology system named KEEP designed to identify and incentivize refinancing opportunities specifically targeting the loans sold to Mr. Cooper.
Rocket asserts that these actions caused Mr. Cooper to lose servicing rights for thousands of mortgages, resulting in prepayment rates about 2.5 times higher than comparable loan pools and financial losses estimated at nearly $100 million due to the diminished value of the remaining servicing rights. The plaintiff characterizes the alleged scheme as a response to UWM’s mounting business difficulties, including margin compression and heavy dependence on continuous origination volume.
UWM has not commented directly but stated to HousingWire that the lawsuit claims are baseless and opportunistic, framing the legal action as retaliation for Rocket's acquisition of Mr. Cooper and the subsequent hiring of Rocket's former head of wholesale by UWM. The company emphasized its belief that Rocket operates on the premise that it owns the consumer relationship rather than the broker relationship.
🚀 Rocket Companies sued UWM for alleged contract breaches regarding 182,000 loans sold earlier this year.
💰 Rocket claims UWM's aggressive refinancing tactics cost them nearly $100 million in lost value.
⚖️ UWM denies the claims, calling the lawsuit baseless and a retaliation for Rocket's recent acquisitions.
🚀 Rocket Companies has sued mortgage rival United Wholesale Mortgage (UWM) in New York State Supreme Court over alleged violations of non-solicitation agreements.
💰 The lawsuit centers on UWM allegedly attempting to win back nearly 182,000 loans purchased by Mr. Cooper from UWM in the first half of 2024 for $773 million.
⚖️ UWM is accused of breaching contract terms that prohibited them from soliciting refinancing on mortgages within the pools sold to Mr. Cooper Group.
📉 Rocket claims these breaches cost Mr. Cooper an additional nearly $100 million due to prepayment rates roughly 2.5 times higher than comparable loan pools without such restrictions.
💸 UWM is accused of offering a 'bounty' incentive program called 'Refi Shield 100', granting its brokers a 1% interest rate reduction specifically for refinancing Mr. Cooper loans.
🤖 The company allegedly launched the proprietary 'KEEP' system to use AI technology to identify and target borrowers with mortgages serviced by Mr. Cooper for refinancing offers.
👔 Chairman Mat Ishbia is alleged to have instructed brokers to prioritize these specific clients, effectively undermining the value of the servicing rights sold to Mr. Cooper.
💡 UWM reportedly launched two additional initiatives in fall 2024, including a 75-basis-point rate reduction program, to reacquire the loans.
📉 Management claims the alleged scheme was part of efforts to manage business difficulties stemming from margin compression and high servicing expenses.
⚠️ Rocket alleges the breach was 'willful and wanton' and directly attributable to Mat Ishbia's instructions rather than isolated broker actions.
🛑 UWM has not issued an immediate comment but told HousingWire that the lawsuit claims are 'baseless and opportunistic'.
🤝 UWM framed the lawsuit as retaliation for Rocket's acquisition of Mr. Cooper and a former Rocket executive joining UWM as a partner.
💹 The core financial dispute involves the decrease in value of mortgage servicing rights when sellers incentivize borrowers to refinance loans they do not service themselves.
⏳ The complaint was filed on Thursday in New York, alleging conduct occurring over the past 18 months following the 2024 loan purchase.
Bullish Signals
Rocket Companies acquired Mr. Cooper Group last year.
Mr. Cooper paid UWM $773 million for 182,000 loans.
UWM launched Refi Shield 100 in fall 2024.
Program offers 1% rate reduction to stimulate volume.
KEEP system identifies opportunities and incentivizes borrowers.
New York Supreme Court filing shows legal engagement.
Risk Factors
$100M losses from high prepayment rates vs. comparables.
UWM flagged breach of non-solicitation on agreed loans.
Fragile model vulnerable to volume drops or competition.
Margin compression and tech costs drove alleged aggression.
'KEEP' system launched desperately for new loan volume.
Bullish Signals
Rocket Companies acquired Mr. Cooper Group last year, expanding its footprint in the mortgage servicing market.
Mr. Cooper paid UWM $773 million to purchase mortgage servicing rights for nearly 182,000 loans with a cumulative unpaid principal balance of about $65 million.
UWM launched the 'Refi Shield 100' incentive program in fall 2024, offering a 100 basis point (1%) reduction on refinance interest rates to stimulate business volume.
UWM deployed a proprietary A-powered tech system called 'KEEP' specifically to identify opportunities and incentivize borrowers, targeting specific loan pools.
Rocket alleges UWM's efforts were part of managing mounting business difficulties due to margin compression, highlighting industry-wide competitive pressures.
The lawsuit was filed Thursday in the Supreme Court of the State of New York, demonstrating a high-level legal engagement with a major competitor.
Risk Factors
Rocket alleges UWM's alleged 'bounty' program and incentive schemes caused Mr. Cooper to lose servicing rights, resulting in nearly $100 million in losses due to prepayment rates that were about 2.5 times higher than comparable loan pools.
The lawsuit claims Rocket incurred these substantial costs because UWM 'flagrantly breached' non-solicitation obligations by directly soliciting refinancing on loans it had explicitly agreed not to touch.
UWM's business model is described as fragile and heavily dependent on continuously generating origination and refinance volume, suggesting vulnerability if volume dries up or competition intensifies.
Margin compression, rising tech costs, and increased servicing expenses are cited as the drivers behind UWM's alleged aggressive tactics to reacquire loans, indicating significant financial pressure on the company.
UWM launched proprietary tech like the 'KEEP' system specifically to target Mr. Cooper's loan pool in an effort to manage these mounting business difficulties, highlighting a desperate need for new volume.
Rocket Companies acquired Mr. Cooper last year, and the timing of this lawsuit coincides with Rocket's former head of wholesale joining UWM as a partner, suggesting a potential proxy war over market share that could escalate industry competition.
Woda Cooper Companies officially opened Annika Place II, a $19.3 million affordable housing complex located at 1020 Hastings Street in Traverse City, Michigan. The new development consists of 52 rental units designed for low and moderate-income residents earning between 30% and 80% of the area median income. Monthly rents are set between $597 and $1,355, depending on unit size and specific income restrictions, with a developer pledge to maintain these below-market rates for at least 45 years.
This project marks the company’s fifth affordable housing development in the Traverse City area and is part of a larger portfolio of 25 such communities across Michigan. The opening ceremony was attended by local officials, financing partners, and existing residents, coinciding with recent state data highlighting a severe housing shortage in Michigan, where over 119,000 homes are needed and fewer than 11% of first-time buyers can comfortably afford starter homes.
Nineteen of the available units are designated as permanent supportive housing, tied to project-based vouchers from the Michigan State Housing Development Authority. These specific units include wraparound services provided by Goodwill Industries covering financial literacy, homeownership assistance, and personal care support, with all furnishings provided at no cost to residents. The building has already achieved LEED zero energy certification and features a 13-kilowatt rooftop solar array projected to generate approximately 16,242 kilowatt-hours annually.
Currently, the facility is nearly full with a waitlist already forming, signaling high demand for stable housing in the region. Woda Cooper, which operates more than 16,000 units across 365 properties in 19 states, indicated it is actively seeking additional sites in the Traverse City area. Local leaders praised the project as essential for community quality of life and workforce stability, while company executives emphasized that the opening represents a starting line rather than a finish line for future development efforts.
🏠 Woda Cooper opened a $19.3M complex with 52 affordable apartments in Traverse City.
📜 Rents are capped and approved by the state for at least 45 years.
☀️ The LEED Zero building features a solar array generating ~16,000 kWh annually.
👥 Units target low-income residents, with 19 offering free supportive housing services.
📈 Demand is high with a waitlist forming, prompting searches for new sites.
- 🏠 Woda Cooper Companies opened Annika Place II, a $19.3 million complex featuring 52 affordable apartments in Traverse City on Thursday.
- 📜 The developer pledged to maintain below-market rents for the site for at least 45 years, with rent increases requiring approval from the Michigan State Housing Development Authority.
- 🏚️ Michigan currently faces a shortage of over 119,000 homes, and Gov. Gretchen Whitmer is pushing legislative changes to improve affordable housing availability.
- 👥 The complex targets low-to-moderate-income residents earning between 30% and 80% of the area median income, with rents ranging from $597 to $1,355 monthly depending on unit size.
- 🛏️ Of the 52 units, 19 are designated as permanent supportive housing furnished at no cost to residents and connected to wraparound services through Goodwill Industries.
- ☀️ The building earned LEED Zero energy certification and includes a 13-kilowatt rooftop solar array projected to generate about 16,242 kilowatt-hours annually.
- 🗣️ Resident Deb Braden moved into the complex after spending over a year homeless with her dog, expressing relief at finally having a place to call home.
- 🏛️ Traverse City Mayor Amy Shamroe noted that the development reflects ten years of sustained commitment from city commissioners to make affordable housing possible.
- 💼 Warren Call, CEO of Traverse Connect, emphasized that this housing is critical for the region's economy, quality of life, and workforce needs.
- 📈 The site is nearly full with a waitlist already forming, prompting Woda Cooper to search for additional sites in the Traverse City area.
- 👔 Craig Patterson, senior vice president of development, confirmed that rent levels must be approved before any increase can occur under MSHDA regulations.
- 🌱 David Cooper Jr., president of Woda Cooper Companies, described the opening as a starting line rather than a finish line for the building's long-term impact.
Bullish Signals
Opened $19.3M affordable complex with 52 low-income units.
Leads as company's 25th Michigan and 5th Traverse City community.
Features LEED zero energy status and 13-kW solar array.
Nearly full demand with growing waitlist for additional units.
Part of portfolio operating 365 properties across 19 states.
Risk Factors
Only 19 of 52 units offer permanent supportive housing services.
High local demand and waitlists constrain supply at this site.
Rents from $716-$1,355 may be unsustainable amid affordability crisis.
Bullish Signals
Woda Cooper Companies successfully opened Annika Place II, a $19.3 million affordable housing complex in Traverse City.
The project marks the company's 25th affordable housing community in Michigan and its fifth specifically in the Traverse City area.
All 52 units are leased to low-to-moderate income residents earning between 30% and 80% of the area median income.
The complex features LEED zero energy certification with a 13-kilowatt rooftop solar array projected to generate approximately 16,242 kilowatt-hours annually.
Woda Cooper is already seeing strong demand, as the building is nearly full with a waitlist forming for additional units.
The developer is actively searching for additional sites in the Traverse City area to expand their footprint.
Annika Place II is part of a larger portfolio where Woda Cooper operates more than 365 properties and 16,000 units across 19 states.
Nineteen units are designated permanent supportive housing furnished at no cost to residents, providing wraparound services through Goodwill Industries.
Risk Factors
The facility is restricted to 52 units, which are already nearly full with a waitlist forming, indicating high demand exceeds current supply at this specific location.
Rent increases for the affordable units must be approved by the Michigan State Housing Development Authority (MSHDA), limiting the operator's flexibility to adjust rental income based on market conditions or rising costs.
Only 19 of the 52 units are designated as permanent supportive housing, meaning the majority of residents do not receive wraparound services despite the high need in a region with over 119,000 homeless homes.
Monthly rents range from $716 to $1,355 for two-bedroom units, which may be unsustainable without strict income verification given the state's broader affordability crisis where only 11% of first-time buyers can afford current starter home costs.
CooperCompanies has released its latest quarterly financial results, demonstrating revenue and adjusted earnings per share that met or slightly exceeded market expectations. The growth was primarily driven by steady demand in its two core segments: CooperVision, which focuses on contact lenses and care products, and CooperSurgical, which specializes in women's health and reproductive medicine solutions. Management highlighted the continued strength of silicone hydrogel contact lenses, daily disposables, and fertility-related medical devices as key performance drivers, noting that these consumable-based products provide predictable recurring revenue streams.
The company reiterated its strategic focus on innovation, geographic expansion, and operational efficiency to support future earnings growth. CooperCompanies noted a shift toward higher-value lens materials and a broader portfolio in women's health, including assisted reproductive technology and minimally invasive gynecologic surgery, which benefits from long-term demographic trends like an aging population and rising infertility rates. As of October 5, 2026, the stock traded at approximately $250 per share on the New York Stock Exchange, reflecting investor interest in its exposure to structurally growing healthcare subsectors such as vision care and fertility treatments.
However, investors are advised to consider potential risks including pricing pressure from competitors, regulatory scrutiny in international markets, and macroeconomic factors that could impact mid-cap US equities. The company maintains a global footprint with significant revenue generated in the United States, supplemented by operations in Europe, Asia-Pacific, and emerging markets. This geographic diversification allows CooperCompanies to capitalize on worldwide demand for vision correction and fertility services, though it also exposes the firm to currency fluctuations and varying local market dynamics. Overall, the article presents a balanced view of the stock's strengths in recurring revenue models versus potential headwinds in the healthcare sector.
📈 Revenue and adjusted EPS met or slightly exceeded market expectations.
👁️ Growth driven by daily disposable lenses and surgical innovations.
💰 Recurring consumable sales ensure predictable cash flows for investors.
⚠️ Investors face risks like pricing pressure and regulatory scrutiny.
🌍 Operations span US markets with significant international exposure.
📈 CooperCompanies reported quarterly revenue and adjusted earnings per share that met or slightly exceeded market expectations.
💼 The company highlighted steady demand for contact lenses, lens care products, and its women’s health portfolio as key growth drivers.
📊 Stock price was approximately $250.00 USD per share on the NYSE as of May 10, 2026, according to Reuters data.
🧐 The business operates primarily through two segments: CooperVision (eye care) and CooperSurgical (women’s health).
💰 Revenue models focus on recurring sales from consumable products like daily disposable lenses and surgical disposables.
🌍 Operations generate significant revenue from the US with additional contributions from Europe, Asia-Pacific, and emerging markets.
🔬 Key growth in CooperVision stems from silicone hydrogel lenses and daily disposables which support margin expansion.
👶 CooperSurgical growth is driven by trends in assisted reproductive technology and minimally invasive gynecologic surgery.
🛠️ Management strategy includes a focus on innovation, geographic expansion, and operational efficiency to sustain future earnings.
⚖️ Investors should weigh risks such as pricing pressure, regulatory scrutiny, and technological changes alongside growth prospects.
📉 International operations expose the firm to currency fluctuations and local regulatory dynamics.
👀 US investors gain exposure to structurally growing healthcare subsectors through a diversified product mix.
🔎 The recurring revenue profile supports predictable cash flows attractive to both income and growth-oriented investors.
⚠️ Execution on innovation and margin management will likely continue to drive stock performance alongside broader market trends.
⚖️ Past performance is not indicative of future results, and this article does not constitute investment advice.
Bullish Signals
Revenue and EPS met or slightly beat market expectations.
Contact lens and women's health demand drove top-line growth.
Management targets innovation, expansion, and efficiency for future earnings.
Rising myopia, aging population, and fertility services boost trends.
Daily disposables drive ASP growth and margin expansion.
CooperSurgical leverages ART and surgery trend growth.
Risk Factors
International exposure to currency, regulatory, and market risks.
Pricing pressure, scrutiny, and tech changes threaten value.
Future tied to innovation execution and margin management.
Healthcare and equity trends could hurt stock performance.
Intense competition in growing healthcare segments remains a risk.
Bullish Signals
CooperCompanies reported quarterly revenue and adjusted earnings per share that met or slightly exceeded market expectations.
Steady demand for contact lenses, care products, and the women's health portfolio served as key drivers for top-line performance.
Management reiterated a strategic focus on innovation, geographic expansion, and operational efficiency to support future earnings growth.
The company benefits from structurally growing trends such as rising myopia rates, an aging population, and increasing demand for fertility services.
A shift toward daily disposable lenses and higher-value materials has supported average selling price growth and margin expansion.
CooperVision's bundled offering of contact lenses and care products creates a predictable recurring revenue stream attractive to investors.
CooperSurgical is capitalizing on long-term trends in assisted reproductive technology, minimally invasive surgery, and diagnostic testing.
Risk Factors
The article explicitly notes that international operations expose CooperCompanies to currency fluctuations, regulatory changes, and local market dynamics.
Investors are cautioned to consider factors such as pricing pressure, regulatory scrutiny, and the pace of technological change when evaluating the stock.
The company's future performance remains tied to execution risks regarding innovation, margin management, and international expansion.
The article warns that broader healthcare and equity-market trends could negatively impact the stock's performance.
Competitive intensity is cited as a potential risk within CooperCompanies' structurally growing healthcare segments.
Tata Capital Limited announced that Manish Chourasia, who served as Chief Operating Officer (COO) for Corporate and Cleantech Finance, is resigning to pursue an external opportunity. The resignation becomes effective on May 11, 2026, following his tenure of nearly 11 years with the company. Chourasia originally joined Tata Capital on July 15, 2015, as Managing Director of Tata Cleantech Capital Limited and assumed his current role after the merger of Tata Cleantech Capital into Tata Capital on January 1, 2024. During his time at the firm, he oversaw operations in corporate finance and cleantech financing, sectors that have gained strategic importance due to growing investments in renewable energy and infrastructure development within India.
The departure has been formally disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with filings submitted to both the BSE Limited and the National Stock Exchange of India on May 6, 2026. The disclosure was signed by Sarita Kamath, Chief Legal and Compliance Officer and Company Secretary at Tata Capital, and categorizes Chourasia as Senior Management Personnel in accordance with SEBI regulations. In his resignation letter addressed to Rajiv Sabharwal, the outgoing executive expressed gratitude for the support received during his tenure and committed to ensuring a smooth and thorough handover of responsibilities before his departure date.
Tata Capital noted that while no successor has been announced for the role yet, the transition occurs against a backdrop of expanding activities in non-banking financial companies across infrastructure financing, corporate lending, and clean energy projects. As competition intensifies within the NBFC sector, the firm has continued to strengthen its presence in lending and sustainability-linked financial services, making this leadership change a notable event for stakeholders monitoring the corporate and cleantech financing segment. The filing includes supporting annexures, such as a copy of Chourasia’s resignation letter, submitted pursuant to SEBI Master Circular requirements governing listed entities.
📅 Manish Chourasia resigns as COO effective May 11, 2026 after 11 years.
🔄 His role merged Cleantech and Corporate Finance prior to departure.
✍️ Formal filings to SEBI were signed by the Chief Legal Officer.
💼 Chourasia thanked leadership and promised a smooth transition of duties.
📅 Tata Capital COO Manish Chourasia resigned to pursue an external opportunity effective May 11, 2026.
🕐 He will exit after nearly 11 years with the company, having joined as Managing Director in July 2015.
🔄 His role was updated from MD of Tata Cleantech Capital to COO for Corporate and Cleantech Finance following a merger on January 1, 2024.
📜 The resignation was formally disclosed via filings submitted to BSE and NSE under SEBI regulations on May 6, 2026.
✍️ The official disclosure document was signed by Sarita Kamath, the company's Chief Legal and Compliance Officer.
💼 Chourasia oversaw Corporate and Cleantech Finance departments during his tenure at the NBFC.
🤝 In his resignation letter addressed to Rajiv Sabharwal, he thanked leadership for support before departing.
🧹 He committed to ensuring a smooth and thorough handover of responsibilities prior to his exit date.
📄 The filing includes supporting annexures such as a copy of the official resignation letter submitted by Chourasia.
⚖️ The departure is categorized under senior management personnel changes per SEBI Master Circular requirements.
🌱 His work covered strategic areas including renewable energy investments and infrastructure financing growth.
📉 No successor has been announced for the COO position by Tata Capital as of the filing date.
🏗️ The transition occurs amidst a broader sectoral focus on expanding corporate lending and clean energy projects.
💡 Corporate and cleantech financing is recognized as an increasingly important segment for Indian financial institutions.
⚙️ Tata Capital continues to strengthen its lending and sustainability-linked services despite intensifying NBFC competition.
🗓️ Chourasia's resignation letter highlights his long-standing association with the organization before this leadership transition.
🏢 The disclosure marks a significant change within the company’s financing business leadership structure.
👋 The move signifies the end of an era for one of the firm's longest-serving executive leaders.
Resignation during expansion timing disrupts critical growth.
Ongoing SEBI scrutiny complicates governance disclosures.
Investors question management retention in competitive sector.
Bullish Signals
Chourasia thanked Tata Capital leadership for their support during his nearly 11-year tenure, reflecting strong internal relationships and a positive culture.
During his time at the company, he worked across corporate finance and cleantech financing operations, strategic areas gaining importance amid growing investments in renewable energy and infrastructure financing.
Tata Capital has continued to strengthen its presence across lending, infrastructure financing, and sustainability-linked financial services as competition intensifies within the NBFC sector.
Chourasia pledged to ensure a smooth and thorough handover of responsibilities before his departure, ensuring business continuity during the transition.
Risk Factors
Key executive transition risk: Senior leadership change with no successor announced yet could lead to operational uncertainty or disruption in core financing operations.
Loss of institutional knowledge: Manish Chourasia is departing after nearly 11 years, potentially taking valuable relationships and experience regarding corporate and cleantech finance.
Strategic timing concern: The resignation occurs while Tata Capital actively expands into critical growth areas like infrastructure financing and clean energy projects where expertise is vital.
Regulatory disclosure burden: The filing highlights ongoing scrutiny under SEBI regulations, indicating that any material governance change must be formally disclosed to BSE and NSE.
Leadership stability signal: Departure of the COO amidst intensifying sector competition may raise questions among investors regarding management retention strategies.
The Cooper Companies, Inc. (COO), a large-cap medical device firm headquartered in California with a market capitalization of $13.9 billion, operates through two main segments: CooperVision and CooperSurgical. The company manufactures contact lens wearers, fertility products, medical devices, contraception, and cryostorage services. Despite its substantial size and industry influence, COO stock has experienced significant recent volatility, trading 20.9% below its 52-week high of $89.83 recorded on December 5, 2025. Over the past three months, the stock declined 12.3%, lagging behind the Dow Jones Industrials Average, which saw only a 2.4% decline in the same period. Looking further back over the last 52 weeks, COO shares have fallen 12.5% compared to the DOWI’s gain of 13.2%.
Technical indicators and recent earnings results have contributed to this downward trend. Since the start of the current month, shares have traded below both their 200-day and 50-day moving averages, signaling bearish momentum. Following its Q1 2026 earnings release on March 5, COO shares dropped 2.2%, with a further 4.6% decline in the subsequent trading session as investor confidence waned. While the company reported revenue increases of nearly 6% year-over-year to reach $1 billion and saw adjusted earnings per share rise 20% to $1.10, beating Wall Street estimates, investors remained concerned about weak organic revenue growth and sluggish business performance in the Asia Pacific region.
Comparatively, Cooper Companies has underperformed against its peer, Align Technology, Inc. (ALGN), which has grown 2% over the past year. Despite this recent decline, sentiment toward COO remains moderately optimistic with a consensus analyst rating of "Moderate Buy" among the 18 analysts covering the stock. The mean price target stands at $90.81, suggesting potential upside of approximately 27.8% from current price levels. The article concludes with a standard disclosure that Sristi Jayaswal held no positions in the securities mentioned and notes the information is for informational purposes only.
🏢 Cooper Companies is a $13.9B medical devices manufacturer focused on contact lenses and fertility.
📉 Shares fell 20.9% from highs, lagging the Dow despite mixed Q1 earnings with revenue up 6%.
⚠ Weak organic growth in Asia Pacific concerns investors following mixed quarterly results.
🎯 Analysts rate it "Moderate Buy" with a $90.81 price target suggesting 27.8% upside.
🏢 The Cooper Companies (COO), a California-based manufacturer, specializes in contact lens wearers, fertility products, and medical devices with a market cap of $13.9 billion.
💰 As a large-cap stock valued over $10 billion, COO holds significant influence within the medical instruments and supplies industry.
📉 COO shares are currently down 20.9% from their 52-week high of $89.83 reached on Dec. 05, 2025.
📊 The company has experienced a downward trajectory, declining 12.3% over the past three months while lagging behind the Dow Jones Industrials Average.
📈 Over the past 52 weeks, COO stock fell 12.5%, contrasting with the Dow's 13.2% gain during the same period.
📉 Technical indicators show bearish momentum as shares trade below their 200-day and 50-day moving averages.
📅 On Mar. 5, COO shares dropped 2.2% after releasing mixed Q1 2026 earnings that saw revenue increase 6% to $1 billion.
💰 Adjusted EPS for the quarter rose 20% year-over-year to $1.10, beating Wall Street estimates, but investors expressed concern over weak organic revenue growth and slower business in Asia Pacific.
📉 Stock dropped another 4.6% in the subsequent trading session due to declining investor confidence following the earnings report.
⚖️ When compared to peer Align Technology (ALGN), which saw its stock grow 2% over the past year, COO has underperformed significantly.
🏆 Among the 18 analysts covering the stock, the consensus rating is a "Moderate Buy" with moderately optimistic sentiment.
🎯 The mean price target of $90.81 suggests 27.8% upside potential from current price levels.
⚠️ Investors are watching closely for potential challenges in the Asia Pacific region affecting organic growth rates.
Risk Factors
Stock declined 20.9% from 52-week high despite large-cap status.
Underperformed Dow Jones (+13.2%) and rival Align Technology (ALGN).
Dropped 4.6% post-earnings citing weak Asia Pacific revenue growth.
Concerns over market challenges threaten long-term sustainability despite EPS beat.
Bullish Signals
The company reported revenue growth of nearly 6% year-over-year, reaching $1 billion which was in line with Wall Street estimates.
Adjusted earnings per share (EPS) for the quarter rose 20% from the prior year's quarter to $1.10, successfully beating Wall Street estimates.
Analysts maintain a 'Moderate Buy' consensus rating with a mean price target of $90.81, suggesting potential upside from current levels.
Risk Factors
COO stock has declined 20.9% from its 52-week high of $89.83 reached on Dec. 05, 2025, indicating significant weakness despite the company's large-cap status.
The stock continues to underperform both the Dow Jones Industrials Average, which gained 13.2% over 52 weeks versus COO's 12.5% decline, and its peer Align Technology, Inc. (ALGN), which grew 2% over the past year.
COO shares are trading below its 200-day and 50-day moving averages since the start of the month, signaling sustained bearish momentum and negative technical sentiment.
Following its mixed Q1 2026 earnings on Mar. 5, COO stock dropped another 4.6% due to investor concerns over weak organic revenue growth and slower business in the Asia Pacific region.
Despite beating Wall Street estimates with adjusted EPS of $1.10 rising 20%, investors remained focused on underlying challenges in key markets that may impact long-term sustainability.
CooperCompanies, a global medical device firm traded on Nasdaq under the ticker COO, announced on May 4, 2026, that it has appointed Paul Keel as an independent director to its Board of Directors. The appointment is effective July 1, 2026, and Mr. Keel will also serve on the Audit Committee. Colleen Jay, Chair of the Board, welcomed Mr. Keel, highlighting his background as a CEO in the medical device sector and his experience leading complex global operations as key assets for executing the company's strategy to create long-term value.
Paul Keel joins CooperCompanies following his tenure as President and Chief Executive Officer of Envista Holdings Corporation since 2024. His prior leadership roles include serving as CEO of Smiths Group plc from 2021 to 2024. Mr. Keel brings a wealth of experience from his 16-year career at 3M, where he held various leadership positions such as Group President of 3M Consumer Business and President of 3M Medical, as well as roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College.
CooperCompanies is headquartered in San Ramon, California, and operates through two primary business units: CooperVision, which is a leader in the contact lens industry, and CooperSurgical, a leading fertility and women's healthcare company. The company employs over 15,000 people, sells products in more than 130 countries, and impacts the lives of over fifty million individuals annually. This press release concludes with standard forward-looking statement disclaimers regarding future actions and performance, noting that these statements are subject to risks and uncertainties detailed in the company's SEC filings.
📅 Paul Keel joins CooperCompanies as an independent director effective July 1, 2026.
👔 He will serve on the Audit Committee following his CEO roles at Envista and Smiths Group.
🏥 CooperCompanies leads contact lenses and fertility care, employing over 15,000 people globally.
🏢 CooperCompanies, a leading global medical device company headquartered in San Ramon, CA, announced the appointment of Paul Keel as an independent director effective July 1, 2026.
📊 Upon joining, Mr. Keel will serve on the Company's Audit Committee to oversee financial reporting and internal controls.
🗣️ Colleen Jay, Chair of the Board, expressed delight at welcoming Mr. Keel, citing his CEO experience in the medical device sector as a significant asset for executing strategy and creating long-term value.
💼 Paul Keel most recently served as President and Chief Executive Officer of Envista Holdings Corporation since 2024.
🔙 Prior to his role at Envista, Mr. Keel was CEO of Smiths Group plc from 2021 to 2024.
🏭 His extensive career includes a 16-year tenure at 3M in various leadership roles such as Group President of Consumer Business and President of Medical.
🎓 Mr. Keel holds an MBA from Harvard Business School and a BA in Economics from Carleton College, bringing strong educational credentials to the board.
👥 CooperCompanies operates through two primary business units: CooperVision, the leader in contact lenses, and CooperSurgical, focused on fertility and women's healthcare.
🌍 The company employs over 15,000 people worldwide, sells products in more than 130 countries, and impacts over fifty million lives annually.
⚠️ The press release includes standard forward-looking statements regarding the Company's strategies, plans, and potential risks associated with future market conditions.
Bullish Signals
Cooper Companies appoints Paul Keel as independent director effective July 1, 2026.
Keel brings CEO experience from Envista Holdings and Smiths Group plc.
Board Chair Colleen Jay praises his track record in value creation.
Keel joins Audit Committee to strengthen governance structure.
Cooper Companies employs 15,000+ people selling products in 130 countries.
Risk Factors
Citi lowers CooperCompanies target from $87 to $80.
CooperSurgical lacks explicit lead status despite lens dominance.
Forward-looking statements warn results may miss due to market risks.
Bullish Signals
CooperCompanies has appointed Paul Keel, a seasoned CEO with experience leading complex global operations in the medical device sector, to its Board of Directors as an independent director effective July 1, 2026.
Mr. Keel brings significant leadership experience from his recent role as CEO of Envista Holdings Corporation and previous tenures at Smiths Group plc, General Electric, and McKinsey & Company, which will be a major asset for executing the company's strategy.
Chair of the Board Colleen Jay expressed strong enthusiasm about Mr. Keel's background, highlighting his proven track record in driving long-term value creation for patients, customers, and shareholders.
Paul Keel is also being appointed to serve on the Audit Committee, further strengthening the company's governance structure upon his joining the board.
CooperCompanies continues to demonstrate its scale and impact as a leading global medical device company headquartered in San Ramon, CA, with a workforce of more than 15,000 employees selling products in over 130 countries.
Risk Factors
CooperCompanies' stock price target was lowered from $87 to $80 by analyst firm Citi, indicating deteriorating investor sentiment or valuation concerns.
While CooperVision is described as a leader in contact lenses, the company does not have an explicit lead position mentioned for its other business unit, CooperSurgical, which focuses on fertility and women's healthcare.
The appointment of Paul Keel to the board is framed around executing strategy and creating long-term value, but forward-looking statements explicitly warn that future results could materially differ due to market conditions and uncertainties.
CooperCompanies, a leading global medical device company headquartered in San Ramon, California, announced today it will release its second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the publication of these results, the company will host a conference call to discuss the reported figures and current corporate developments at 5:00 PM ET. Investors and analysts can access simultaneous audio webcasts and replays of this discussion via the investor relations website at www.investor.coopercos.com or dial in using the number 800-715-9871 with conference ID 6529381.
The San Ramon-based company operates two primary business units: CooperVision, a trusted leader in the contact lens industry, and CooperSurgical, a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at critical healthcare moments. With a global workforce exceeding 15,000 employees, CooperCompanies sells its products in over 130 countries and aims to positively impact more than fifty million lives annually through its mission to help people experience life's beautiful moments.
This announcement serves as a standard corporate update regarding upcoming earnings reporting schedules rather than introducing new financial data or strategic changes. The press release notes that the editorial teams of Markets Insider and Business Insider were not involved in the creation of this post, ensuring the information is presented directly from the company via GlobeNewswire. While the article includes a section titled "Notable healthcare headlines for the week" listing various analyst actions such as Mizuho Securities' buy rating, Citi's price target reduction to $80, and Morgan Stanley's hold rating, these items are contextual additions rather than core details of CooperCompanies' immediate announcement.
📅 Earnings results released June 4, 2026 at 4:15 PM ET.
📞 Join the call via 800-715-9871 or www.investor.coopercos.com.
🏢 Global leader employing 15,000 people across two medical units.
📅 CooperCompanies announced it will release its second quarter 2026 financial results on Thursday, June 4, 2026.
🕐 The earnings call is scheduled for 4:15 PM ET followed by a conference call at 5:00 PM ET.
📞 Investors can dial into the conference using number 800-715-9871 and conference ID 6529381.
🌐 A live webcast and subsequent replay of the call are available at www.investor.coopercos.com.
🏢 CooperCompanies operates as a leading global medical device company headquartered in San Ramon, CA.
👥 The company employs more than 15,000 people and sells products in over 130 countries.
💡 Its portfolio positively impacts the lives of over fifty million people annually.
🔬 CooperCompanies consists of two main business units: CooperVision and CooperSurgical.
👁️ CooperVision is a trusted leader in the contact lens industry focused on improving daily vision.
👩⚕️ CooperSurgical is a leading fertility and women's healthcare company dedicated to supporting families during critical moments.
📈 The Nasdaq ticker symbol for the company is COO.
🎯 Recent analyst activity includes a buy rating from Mizuho Securities and a hold rating from Morgan Stanley.
Bullish Signals
CooperCompanies, a leading global medical device company with over 15,000 employees, sells products in more than 130 countries and positively impacts over fifty million lives annually.
The company operates two trusted business units, CooperVision and CooperSurgical, which are dedicated to improving vision and women's fertility healthcare.
Risk Factors
A recent analyst downgrade by Citi lowered CooperCompanies' price target from $87 to $80, indicating bearish sentiment among investors.
Analyst outlook remains cautious with Morgan Stanley maintaining a Hold rating rather than upgrading the stock.
The release of upcoming Q2 2026 financial results on June 4, 2026, may reveal further weakness if trends persist.
Cooper Companies (COO) has experienced recent share price pressure, declining 0.9% over the past day and roughly 17% over the last three months, with prices recently closing at US$69.66 and a market value of approximately US$13.7 billion. The healthcare corporation operates through two primary business units: CooperVision (CVI), which generated US$2.79 billion in revenue focused on contact lenses for conditions including astigmatism, presbyopia, and myopia; and CooperSurgical (CSI), contributing US$1.36 billion in revenue related to women's and family health products such as fertility services, medical devices, contraception, and cryostorage. Geographically, the company reported annual revenues of US$2.75 billion from the United States and US$2.42 billion from Europe, resulting in a total annual revenue of US$4.15 billion with reported net income growth of 16.6% to reach US$401.4 million.
Despite these fundamentals showing revenue growth of 5.1%, recent trading momentum is fading compared to longer-term historical returns, which show a three-year total shareholder return of 25.1% and a five-year return of 28.7%. While some analyst narratives suggest a fair value price of US$91.80 based on forecasts for earnings, margins, and buybacks that would imply the stock is undervalued, the current price-to-earnings (P/E) ratio of 33.9x significantly exceeds industry peers at 22.2x, the US medical equipment average of 26.7x, and even a fair multiple of 28.2x. This premium suggests that while improved cash generation is anticipated with free cash flow projected around US$2 billion over the next three years as capital expenditures wind down following the MyDAY capacity ramp, the valuation gap requires precise alignment between growth expectations, profitability, and share count reduction.
Investors are advised to consider key risks to the upside potential, specifically whether MyDAY's ramp converts efficiently into sustained sales and if demand for fertility products and PARAGARD continues without weakening, as these factors could derail the anticipated fair value narrative. The company's high P/E multiple also means there is less room for error if growth underdelivers compared to peers. Simply Wall St suggests that amidst this valuation uncertainty, investors looking to reassess healthcare exposure might consider widening their search to other healthcare AI stocks, dividend fortresses, high-quality undervalued stocks, or resilient companies with low risk scores, noting that the analysis is based on historical data and analyst forecasts without constituting a direct recommendation to buy or sell.
📉 Stock declined 17% over three months with shares facing recent price pressure.
💰 Net income grew 16.6% to $401.4M on $4.15B of annual revenue.
⚠ Valuation premium hinges on product demand and MyDAY capacity efficiency.
📉 Cooper Companies (COO) shares faced price pressure recently, declining 9% over the past month and 17% over the past three months.
💼 The company operates through two main business units: CooperVision generating $2.79 billion and CooperSurgical contributing $1.36 billion.
🌍 Revenue was distributed across regions with US$2.75 billion from the United States and US$2.42 billion from Europe.
📈 Financial performance showed annual revenue growth of 5.1% and net income growth of 16.6%, totaling $401.4 million in net income on $4.15 billion of revenue.
📉 Recent trading momentum is fading with a 3-year total shareholder return of 25.1% and a 5-year return of 28.7%.
🏦 Analysts estimate a fair value of US$91.80 per share, which suggests the current price of $69.66 could be undervalued.
💰 Free cash flow is expected to increase as capital expenditure cycles wind down, with management guiding for approximately $2 billion in free cash flow over three years.
⚠️ The valuation narrative hinges on MyDAY capacity ramp efficiency and maintaining demand for fertility products and PARAGARD.
📊 Cooper Companies currently trades at a P/E ratio of 33.9x, which is higher than peers at 22.2x and the US medical equipment average of 26.7x.
⚖️ Investors must decide if the premium valuation reflects confidence in future earnings or pricing in expectations that are already known.
🔍 Simply Wall St suggests checking out related content including 37 healthcare AI stocks, 13 dividend fortresses, and 61 high quality undervalued stocks.
⚡ This analysis is based on historical data and analyst forecasts without taking into account recent price-sensitive announcements or qualitative material.
Bullish Signals
Cooper net income $401.4m on revenue $4.15b.
Revenue up 5.1%, net income growth 16.6%.
FCF guidance ~$2B over next three years.
Capital expenditure cycle ending boosts cash flow.
Fair value estimate $91.80 vs recent close $69.66.
Cash generation supports debt reduction and buybacks.
Risk Factors
Shares declined ~9% this month and ~17% over three months.
Stock price of $69.66 is below analyst fair value of $91.80.
P/E ratio of 33.9x exceeds peers at 22.2x and sector average of 26.7x.
Valuation depends on MyDAY capacity ramp, which faces uncertainty risks.
Fertility demand from PARAGARD could weaken further.
High P/E leaves no margin for error if growth underperforms peers.
Bullish Signals
Cooper Companies reported net income of US$401.4m alongside annual revenue of US$4.15b, demonstrating strong financial performance.
The company achieved positive growth with a reported annual revenue increase of 5.1% and net income growth of 16.6%.
Management guides for approximately $2 billion in free cash flow over the next three years, reflecting confidence in future cash generation.
Free cash flow is expected to improve as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity.
The company's fair value is estimated at $91.80, significantly above the recent close of $69.66, indicating potential upside potential.
Improved cash generation will support debt reduction and share repurchases, further benefiting shareholders.
Risk Factors
Shares have faced sustained downward pressure, declining approximately 9% over the past month and roughly 17% over the past 3 months.
The current stock price of US$69.66 is significantly below the analyst-led fair value estimate of $91.80, suggesting potential downside if expectations are not met.
Cooper Companies trades at a P/E ratio of 33.9x, which is well above peers at 22.2x and the US Medical Equipment average of 26.7x, indicating limited room for error if growth underdelivers.
Future valuation upside hinges on MyDAY's capacity ramp converting efficiently into sustained sales and fertility/PARAGARD demand not weakening further, which are uncertain risks.
The high valuation premium may reflect overconfidence in future earnings or suggest the market is paying too much for already known expectations.
If growth assumptions underperform, the current P/E multiple leaves no margin for error compared to industry peers.
Cooper Companies (COO) has experienced recent downward pressure on its share price, with declines of 0.9% over the past day, 2.6% over the week, approximately 9% over the month, and about 17% over the last three months. The company closed at US$69.66, representing a market value of roughly US$13.7 billion. Cooper Companies is structured around two primary business segments with distinct healthcare spending profiles: CooperVision (CVI) and CooperSurgical (CSI). CooperVision generated revenue of US$2.79 billion, primarily focused on contact lenses for conditions including astigmatism, presbyopia, and myopia, while CooperSurgical contributed US$1.36 billion tied to women’s and family health products such as fertility services, medical devices, contraception, and cryostorage.
Financially, the company reported annual revenue of US$4.15 billion with a net income of US$401.4 million, marking a 5.1% increase in annual revenue and a 16.6% growth in net income. Regional breakdowns show US$2.75 billion in revenue from the United States and US$2.42 billion from Europe, alongside a segment adjustment of US$1.02 billion noted for investor comparisons. Long-term shareholder returns indicate a challenging outlook, with a 3-year total shareholder return of 25.1% and a 5-year total shareholder return of 28.7%, contrasting with the recent fading momentum seen in the 30-day and 3-month trading periods.
Analyst narratives suggest Cooper Companies could be undervalued with a fair value target of US$91.80, significantly higher than the current close of US$69.66. This valuation gap is predicated on forecasts for improved earnings, margins, share buybacks, and rising free cash flow expected to reach approximately US$2 billion over the next three years as capital expenditure cycles wind down following the ramp-up of MyDAY capacity. However, this positive narrative relies heavily on assumptions such as efficient conversion of MyDAY’s production capacity into sustained sales and stable demand for fertility products and PARAGARD.
Despite the potential upside, valuation metrics present mixed signals that warrant caution. Cooper Companies currently trades at a price-to-earnings (P/E) ratio of 33.9x, which is substantially above its peers at 22.2x, the US medical equipment sector average of 26.7x, and a fair P/E ratio of 28.2x. This premium reflects high expectations for future earnings growth, meaning there may be less room for error if actual performance does not meet projections. Investors are encouraged to consider whether the market has already priced in this future growth or if the stock is mispriced given these elevated multiples and potential risks related to demand weakening in key segments.
📉 Shares fell 17% in three months but analysts target a $91.80 fair value.
💰 Revenue grew 5.1% to $4.15B, though valuation sits at 33.9x peers.
⚠️ Success depends on executing capacity expansion and sustaining fertility product demand.
📉 Cooper Companies (COO) shares have faced recent downward pressure, declining 9% over the past month and approximately 17% over the last three months.
💵 The company closed at US$69.66 with a total market capitalization of around US$13.7 billion.
🏢 Cooper Companies operates through two primary business segments: CooperVision (contact lenses) and CooperSurgical (medical devices, fertility products, and contraceptives).
💰 Reported annual revenue reached US$4.15 billion with net income of US$401.4 million, reflecting 5.1% revenue growth and 16.6% net income growth.
🌍 Revenue is geographically split between US$2.75 billion from the United States and US$2.42 billion from Europe, excluding segment adjustments.
📈 Analysts estimate a fair value of US$91.80 per share, suggesting the current stock is potentially undervalued relative to their forecasts.
🧠 Future free cash flow is expected to increase significantly as capital expenditure cycles wind down, with management guiding approximately US$2 billion over the next three years.
⚠️ The valuation relies on successful execution of capacity expansion at MyDAY and sustained demand for fertility and PARAGARD products.
📊 Current P/E ratio of 33.9x is notably higher than peer average of 22.2x and US medical equipment sector average of 26.7x.
🛠️ Improved cash generation could benefit shareholders through debt reduction and increased share repurchases under management's guidance.
⚖️ Investors face a choice between believing the market misprices future growth or acknowledging that high valuation multiples require flawless execution.
🔍 Simply Wall St analysis identifies 3 key rewards for holding Cooper Companies despite mixed signals regarding price pressure.
💡 The article suggests diversifying into other opportunities such as dividend fortresses, high-quality undervalued stocks, and resilient low-risk portfolios.
⚖️ This content is provided by Simply Wall St and does not constitute financial advice or a recommendation to buy or sell the stock.
Bullish Signals
Cooper Companies reported net income growth of 16.6% on an annual revenue of US$4.15b, demonstrating strong earnings momentum.
Analyst forecasts project approximately $2 billion in free cash flow over the next three years as capital expenditures wind down and MyDAY capacity ramps up.
The company maintains a discount to its fair value estimate of $91.80, suggesting significant upside potential if current valuations correct.
CooperVision generated US$2.79b in revenue focusing on contact lenses for myopia, presbyopia, and astigmatism, while CooperSurgical contributed US$1.36b with exposure to fertility products and contraception.
The company has annual revenue growth of 5.1%, indicating sustained demand across its healthcare segments.
Risk Factors
The stock has faced significant downward price pressure, declining approximately 17% over the past three months and entering bear market territory relative to its recent highs.
Despite reported growth, the current P/E ratio of 33.9x sits well above peers at 22.2x and the US medical equipment average at 26.7x, leaving little room for error if future growth underdelivers.
The positive valuation narrative hinges critically on MyDAY's capacity ramp converting efficiently into sustained sales, a risk that could easily derail expected upside.
Demand for fertility products and PARAGARD could weaken further, which would directly threaten the revenue stream from CooperSurgical (CSI).
Analyst forecasts rely on an almost perfect alignment of growth, profitability, and share count shrinking, suggesting high sensitivity to any single metric missing expectations.
The company's current price of US$69.66 is significantly below the fair value estimate of $91.80, implying the market may have already priced in risks not yet reflected in analyst targets.
The provided text appears to be an error message from MarketBeat rather than an actual news article about The Cooper Companies, Inc. ($COO) shares being acquired by Davenport & Co LLC. The content indicates that a security service is verifying the user and warns that JavaScript and cookies must be enabled to continue, suggesting the intended article content was never loaded or is blocked by the verification process. Without access to the actual news details regarding the acquisition terms, share volume, transaction price, or any other substantive information, it is impossible to write a summary based on the provided input. A proper summary would require the full text of the original article from MarketBeat.
🚫 No financial data or news details were found in the text.
🔒 Only a security verification message is present in the input.
❌ A valid summary cannot be generated without substantive content.
No meaningful content was found in the provided article snippet as it contains only a security verification message and no financial data or news details.
Due to the lack of substantive information, no bullet-point summary can be generated according to your rules.
Please provide the full text of the article regarding The Cooper Companies, Inc. ($COO) for an accurate summary.
Rocket Companies has fallen approximately 20% since the beginning of March 2026, underperforming despite a broader rally in real estate sectors, which are currently up roughly 7% year to date. Josh Brown, CEO and co-founder of Ritholtz Wealth Management, argues that this decline may present an opportunity for a bounce. Brown highlighted the company's strategy of acquiring assets during what he termed a "mortgage nuclear winter," specifically noting the completion of a $14 billion acquisition of Mr. Cooper in October and an earlier purchase of Redfin.
According to Brown, these acquisitions allow Rocket to nearly service 10 million homeowners, positioning it as a potential dominant mortgage-to-housing platform that is moving in the right direction. The article suggests that stocks like Rocket could see further upside if interest rates are cut again by the Federal Reserve or if Treasury yields retreat from levels influenced by geopolitical tensions such as the Iran war. However, current market expectations for a Fed policy meeting next week are currently priced in at no change based on CME Group’s FedWatch tool data.
The article concludes with standard disclaimers regarding financial advice, noting that Brown may hold securities in the company discussed and that opinions expressed do not reflect CNBC's official policy.
Rate cuts or yield drops could further boost stocks.
Risk Factors
Shares down 20% YTD amid real estate sector rally.
Completed costly Mr. Cooper acquisition for over $14 billion.
Federal Reserve expected to hold rates elevated.
Bullish Signals
Rocket Companies is well-positioned for a potential stock bounce following its latest string of acquisitions, according to analyst Josh Brown.
The company recently completed the $14 billion acquisition of Mr. Cooper, expanding its services to nearly 10 million homeowners.
Rocket also acquired Redfin earlier, helping it build toward its goal of becoming a dominant mortgage-to-housing platform.
With the broader real estate industry rallying and the State Street Real Estate Select Sector SPDR ETF up 7% year to date, Rocket could see upside potential.
Future interest rate cuts from the Federal Reserve or Treasury yields pulling back could further boost stocks in the sector.
Risk Factors
Rocket Companies shares are down approximately 20% year-to-date despite a broader rally in the real estate sector.
The company recently completed costly acquisitions, including Mr. Cooper for more than $14 billion last October and Redfin earlier.
Traders expect no move from the Federal Reserve at its upcoming policy meeting, potentially keeping interest rates elevated.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)